A nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy (ARCADE)
Dutch Pancreatic Cancer Group
(2022) Trials, volume 23, issue 1
(Article)
Abstract
BACKGROUND: Disease recurrence is the main cause of mortality after resection of pancreatic ductal adenocarcinoma (PDAC). In 20-30% of resected patients, isolated local PDAC recurrence occurs. Retrospective studies have suggested that stereotactic body radiation therapy (SBRT) might lead to improved local control in these patients, potentially having a beneficial effect
... read more
on both survival and quality of life. The "nationwide randomized controlled trial on additional treatment for isolated local pancreatic cancer recurrence using stereotactic body radiation therapy" (ARCADE) will investigate the value of SBRT in addition to standard of care in patients with isolated local PDAC recurrence compared to standard of care alone, regarding both survival and quality of life outcomes. METHODS: The ARCADE trial is nested within a prospective cohort (Dutch Pancreatic Cancer Project; PACAP) according to the 'Trials within Cohorts' design. All PACAP participants with isolated local PDAC recurrence after primary resection who provided informed consent for being randomized in future studies are eligible. Patients will be randomized for local therapy (5 fractions of 8 Gy SBRT) in addition to standard of care or standard of care alone. In total, 174 patients will be included. The main study endpoint is survival after recurrence. The most important secondary endpoint is quality of life. DISCUSSION: It is hypothesized that additional SBRT, compared to standard of care alone, improves survival and quality of life in patients with isolated local recurrence after PDAC resection. TRIAL REGISTRATION: ClinicalTrials.gov registration NCT04881487 . Registered on May 11, 2021.
show less
Download/Full Text
Keywords: Carcinoma, Pancreatic Ductal/radiotherapy, Humans, Neoplasm Recurrence, Local/pathology, Pancreatic Neoplasms/radiotherapy, Pituitary Adenylate Cyclase-Activating Polypeptide, Prospective Studies, Quality of Life, Radiosurgery/adverse effects, Retrospective Studies, Disease recurrence, Pancreatic ductal adenocarcinoma, Isolated local recurrence, PDAC, Stereotactic body radiation therapy, Image-guided radiotherapy, Pancreatic cancer, SBRT, SABR, Pharmacology (medical), Medicine (miscellaneous), Randomized Controlled Trial, Journal Article
ISSN: 1745-6215
Publisher: BioMed Central
Note: Funding Information: The ARCADE trial is funded by the Dutch Cancer Society (KWF; grant number 12568). The Dutch Cancer Society has no role in the design of the study, the collection, analysis, and interpretation of the data, and writing of the manuscript. Publisher Copyright: © 2022, The Author(s).
(Peer reviewed)